Summary of disease and stage risk groups
. | Risk . |
---|---|
Disease | |
AML-favorable cytogenetics | Low |
CLL | Low |
CML | Low |
Indolent B-cell NHL | Low |
ALL | Intermediate |
AML intermediate cytogenetics | Intermediate |
MDS intermediate cytogenetics | Intermediate |
Myeloproliferative neoplasms | Intermediate |
Multiple Myeloma | Intermediate |
Hodgkin lymphoma | Intermediate |
DLBCL/Transformed indolent B-NHL | Intermediate |
Mantle cell lymphoma | Intermediate |
T-cell lymphoma, nodal | Intermediate |
AML adverse cytogenetics | High |
MDS adverse cytogenetics | High |
T-cell lymphoma, extranodal | High |
Stage | |
1st CR | Low |
2nd or subsequent CR | Low |
1st PR | Low |
Untreated | Low |
Chronic-phase CML | Low |
2nd or subsequent PR (if RIC) | Low |
2nd or subsequent PR (if MAC) | High |
Induction failure | High |
Active relapse | High |
Accelerated or blast-phase CML | High |
. | Risk . |
---|---|
Disease | |
AML-favorable cytogenetics | Low |
CLL | Low |
CML | Low |
Indolent B-cell NHL | Low |
ALL | Intermediate |
AML intermediate cytogenetics | Intermediate |
MDS intermediate cytogenetics | Intermediate |
Myeloproliferative neoplasms | Intermediate |
Multiple Myeloma | Intermediate |
Hodgkin lymphoma | Intermediate |
DLBCL/Transformed indolent B-NHL | Intermediate |
Mantle cell lymphoma | Intermediate |
T-cell lymphoma, nodal | Intermediate |
AML adverse cytogenetics | High |
MDS adverse cytogenetics | High |
T-cell lymphoma, extranodal | High |
Stage | |
1st CR | Low |
2nd or subsequent CR | Low |
1st PR | Low |
Untreated | Low |
Chronic-phase CML | Low |
2nd or subsequent PR (if RIC) | Low |
2nd or subsequent PR (if MAC) | High |
Induction failure | High |
Active relapse | High |
Accelerated or blast-phase CML | High |
ALL indicates acute lymphoblastic leukemia; AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; CML, chronic myelogenous leukemia; CR, complete remission; DLBCL, diffuse large B-cell lymphoma; MAC, myeloablative conditioning; MDS, myelodysplastic syndrome; NHL, non-Hodgkin lymphoma; PR, partial remission; and RIC, reduced-intensity conditioning.